Corvus Pharmaceuticals CRVS Equity method investments (Note 11)
Equity method investments (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's equity method investments (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's equity method investments (note 11)?
- Corvus Pharmaceuticals (CRVS) reported equity method investments (note 11) of $10.5M in Q1 2026.
- How has Corvus Pharmaceuticals's equity method investments (note 11) changed year-over-year?
- Corvus Pharmaceuticals's equity method investments (note 11) decreased by 13.0% year-over-year, from $12.06M to $10.5M.
- What is the long-term trend for Corvus Pharmaceuticals's equity method investments (note 11)?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's equity method investments (note 11) has grown at a -21.6% compound annual growth rate (CAGR), from $37.23M to $10.99M.